Literature DB >> 28669684

Urinary metabolomic analysis of intrahepatic cholestasis of pregnancy based on high performance liquid chromatography/mass spectrometry.

Li Ma1, Xiaoqing Zhang1, Feng Pan2, Yue Cui1, Ting Yang1, Linlin Deng1, Yong Shao3, Min Ding4.   

Abstract

BACKGROUND: Intrahepatic cholestasis of pregnancy (ICP), a pregnancy-related liver disease, leads to complications for both mothers and fetuses. Metabolomic approach has been applied to maternal-fetal medicine. The global metabolomic alterations that are specific in ICP as yet have not been investigated.
METHODS: Based on high performance liquid chromatography/hybrid quadrupole time-of-flight (HPLC/Q-TOF) mass spectrometry, the untargeted metabolomics was used to analyze the changes of urinary metabolites between ICP group and the control group.
RESULTS: One hundred nine variables in positive model and 119 variables in negative model were significantly different (p<0.05) between the ICP group and the control group, with the VIP (variable importance in the project) score>1 by the orthogonal partial least squares discriminant analysis (OPLS-DA). 14 metabolites in positive model and 18 metabolites in negative model were selected and identified based on HMDB (human metabolome database). Most of these metabolites were involved in bile acids biosynthesis and metabolism, hormone metabolism and lipid metabolism. A metabolite panel (MG (22:5), LysoPE (22:5), l-homocysteine sulfonic acid, glycocholic acid and chenodeoxycholic acid 3-sulfate) was contrusted by the binary logistic regression analysis with high diagnostic accuracy for ICP. The area under the receiver operating characteristic curve was 0.988 with the sensitivity of 90.0% and specificity of 93.3%.
CONCLUSIONS: Urinary metabolites allow for the discrimination of ICP from the controls by orthogonal partial least squares discriminant analysis. Therefore, these findings may provide deep insights for the etiopathogenesis of ICP. Moreover, the maternal urinary metabolite panel has the potential to be used as non-invasive biomarkers for the diagnosis of ICP.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Biomarkers; HPLC/Q-TOF; Intrahepatic cholestasis of pregnancy; Metabolomics; Urine

Mesh:

Year:  2017        PMID: 28669684     DOI: 10.1016/j.cca.2017.06.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

Review 1.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

2.  Lipidomics analysis of human follicular fluid form normal-weight patients with polycystic ovary syndrome: a pilot study.

Authors:  Yanna Ban; Haiying Ran; Ying Chen; Li Ma
Journal:  J Ovarian Res       Date:  2021-10-13       Impact factor: 4.234

Review 3.  Application of metabolomics in intrahepatic cholestasis of pregnancy: a systematic review.

Authors:  Zhuoqiao Yang; Mengxin Yao; Chunhua Zhang; Xuan Hu; Yi Zhong; Xiangxiang Xu; Jieyun Yin
Journal:  Eur J Med Res       Date:  2022-09-14       Impact factor: 4.981

4.  Circulatory Metabolomics Reveals the Association of the Metabolites With Clinical Features in the Patients With Intrahepatic Cholestasis of Pregnancy.

Authors:  Wenhu Liu; Qiang Wang; Jinxia Chang; Anup Bhetuwal; Nisha Bhattarai; Xin Ni
Journal:  Front Physiol       Date:  2022-07-11       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.